Whalesbook
The National Company Law Tribunal (NCLT) has granted its approval for the planned merger between Sequent Scientific and Viyash Life Sciences. This significant development paves the way for a combined entity valued at approximately Rs 8,000 crore, a deal initially announced in September 2024.
Sequent Scientific, a publicly listed company, operates in the animal health sector and reported operating profits of around Rs 100 crore in the financial year 2023-24. Viyash Life Sciences, which is not publicly listed, focuses on making drugs for human health and had operating profits of approximately Rs 150 crore in the same period. It boasts nine manufacturing sites, many of which are approved by the United States Food and Drug Administration (FDA).
The merger is driven by the strategic objective to explore and exploit back-end synergies between the two companies. Carlyle Group, a prominent private equity firm, holds a significant stake in both Sequent Scientific and Viyash Life Sciences, making this a key move for its investment portfolio.
Further reinforcing the merger's progress, Sequent Scientific's public shareholders recently approved the deal with an overwhelming 99.98% majority. Hari Babu Bodepudi, the founder of Viyash Life Sciences and formerly the global chief operating officer of Mylan (now Viatris), will lead the combined entity as its chief executive officer.
Impact:
This approval is expected to create a stronger, more diversified player in the Indian pharmaceutical and animal health landscape. For Sequent Scientific shareholders, it signals potential for enhanced growth and market positioning. The consolidation could lead to operational efficiencies and synergistic benefits, bolstering the combined entity's competitive edge. For the Indian stock market, it reinforces positive sentiment around M&A activities within the healthcare sector. It also presents an opportunity for Carlyle Group to realize further value from its investments. Rating: 7/10
Difficult terms:
National Company Law Tribunal (NCLT): A specialized quasi-judicial body in India tasked with adjudicating corporate matters, including mergers, acquisitions, and insolvency proceedings.
Merger: A corporate strategy where two or more companies combine their operations, assets, and liabilities to form a single, larger entity.
Operating profits: Profits generated from a company's core business activities before accounting for interest expenses and taxes. It reflects the profitability of the company's primary operations.
Synergies: The concept that the combined value and performance of two companies will be greater than the sum of the individual parts. This can be achieved through cost savings, revenue enhancement, or other operational efficiencies.
United States Food and Drug Administration (FDA): A federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food supply, and cosmetics.